<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-112211
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090515
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20090515
<DATE-OF-FILING-DATE-CHANGE>20090515
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>09828869
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Current Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>May&nbsp;15, 2009 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Date of Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Date of earliest event reported) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its
charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s
telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former
address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On
May&nbsp;15, 2009, Pro-Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a news release announcing financial results for the three months ended March&nbsp;31, 2009. A copy of the news release is attached as Exhibit 99.1 to this Current Report
on Form 8-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information in this Current Report (including the exhibit) is furnished pursuant to Item&nbsp;2.02 and shall not be
deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Financial
Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) Shell Company Transactions </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman"
SIZE="2"><U>Exhibit Number</U> </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">News release of Pro-Pharmaceuticals, Inc., dated May&nbsp;15, 2009, entitled &#147;Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results&#148;. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Anthony D. Squeglia</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Anthony D. Squeglia</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Date: May&nbsp;15, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">News release dated May 15, 2009 entitled &#147;Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results&#148;.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>News release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g93463ex99_1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B><I>Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Newton, MA &#150; May&nbsp;15, 2009 &#150; Pro-Pharmaceuticals, Inc. (OTCBB: PRWP)</B>, a developer of carbohydrate-based targeted therapeutic compounds to treat
cancer and fibrosis, today reported its financial results for the first quarter of fiscal 2009. These results are included in the Company&#146;s Quarterly Report on Form 10-Q for the three-month period ended March&nbsp;31, 2009, which has been filed
with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For the three months ended March&nbsp;31, 2009, the Company reported a net loss of $2,859,000, or ($0.06) per share, compared with a net
loss of $2,069,000 or ($0.05) per share for the same period in 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During the three months ended March&nbsp;31, 2009, the Company closed a Series B-1
Redeemable Convertible Preferred Stock round of financing resulting in approximately $1,500,000 of net proceeds. At March&nbsp;31, 2009, the Company had approximately $861,000 of cash and cash equivalents to fund future operations. On May 13, 2009,
the Company completed a closing for gross proceeds of $900,000 on its offering of Series B-2 Redeemable Convertible Preferred Stock (&#147;Series B-2&#148;) for a total of 450,000 shares of Series B-2 and warrants to purchase shares of common stock.
This transaction brings the total raised to 2.7 million of the $6 million commitment of the 10X Fund. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Research and development expense for the first
quarter of 2009 was $153,000, compared with $422,000 for the same period in 2008. The decrease was due primarily to overall lower activity in clinical and pre-clinical programs as a result of cost containment measures. The Company expects to
initiate its Phase III trial as soon as it raises additional funds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">General and Administrative expense was $1,581,000, compared with $990,000 for the same
period in 2008. The increase was due primarily to a one-time charge related to an employee separation agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT
FACE="Times New Roman" SIZE="2">&#147;We have a clear pathway to submit a new drug application (NDA) to the Food and Drug Administration (FDA) to commercialize DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>,&#148; said Theodore
Zucconi, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals. &#147;Results of our pre-clinical studies and clinical trials show significant clinical and economic benefits to cancer patients by adding DAVANAT<FONT FACE="Times New Roman"
SIZE="1"><SUP>&reg;</SUP></FONT> to their chemotherapy treatment. Results include extended patient survival, improved quality of life, reduced side effects, and lower costs associated with patient care. For example, no mucositis serious adverse
events (SAEs), grades 3, 4 or 5, were found in approximately 100 cancer patients that were treated with DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&nbsp;</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2">and 5-FU. Typically, up to 40% of patients treated with 5-FU get mucositis. SAEs of grade levels 3, 4, or 5 can result in life threatening events, in-patient hospitalization, persistent or significant disability,
and/or death.&nbsp;5-FU is one of the most widely used chemotherapy drugs in the world and is used to treat various types of cancers, including colorectal, breast and gastrointestinal. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">&#147;We plan to initiate a Phase III trial for approximately 300 late-stage colorectal cancer patients this year.
As part of this trial, we expect to conduct a pharmacokinetic (PK) analysis of approximately 60 patients, which may allow the Company to file an NDA for DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> as an adjuvant when
administered with 5-FU. Adjuvants are pharmacological or immunological agents that modify the effect of drugs. We also are actively engaged in discussions with potential partners, that include large pharmaceutical companies, distributors for
DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> in the Mid-East and Korea and have initiated discussions with potential partners in South America,&#148; said Zucconi. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"><B>About DAVANAT<FONT FACE="Times New Roman"
SIZE="1"><SUP>&reg;</SUP></FONT> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP>
</FONT>, the Company&#146;s lead product candidate, is a carbohydrate polymer composed of mannose and galactose.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>&#146;s mechanism of action is based on interacting with
lectins on the cell surface.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> targets specific lectin receptors (galectins) that are over-expressed on cancer cells. Current research indicates that galectins affect cell
development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> is a drug that is not yet approved for commercial use by the
FDA. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pro-Pharmaceuticals,
OTCBB: PRWP, is engaged in the discovery, development and commercialization of carbohydrate therapeutics for advanced treatment of cancer and fibrosis.&nbsp;Initially, the product pipeline is focused on increasing the efficacy and decreasing the
toxicity of chemotherapy drugs.&nbsp;The Company is headquartered in Newton, Mass.&nbsp;Additional information is available at www.pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words &#147;believes,&#148; &#147;anticipates,&#148;
&#147;plans,&#148; &#147;expects,&#148; and similar expressions, constitute forward-looking statements as defined in the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are
based on management&#146;s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or
business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential
products; uncertainties associated with pre-clinical and clinical trials of our product candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales,
distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of
government regulation of our activities, facilities and personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses
and accumulated deficit; and economic conditions related to the biotechnology and biopharmaceutical industry. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on
forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">More information about those risks and uncertainties is contained and discussed in the &#147;Management Discussion and
Analysis of Financial Condition and Results of Operations&#148; and &#147;Risk Factors&#148; sections of the Company&#146;s most recent quarterly or annual report and in the Company&#146;s other reports filed with the Securities and Exchange
Commission. The forward-looking statements represent the Company&#146;s views as of the date of this news release and should not be relied upon to represent the Company&#146;s views as of a subsequent date. While the Company anticipates that
subsequent events may cause the Company&#146;s views to change, the Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contact:
Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DAVANAT is a registered trademark of Pro-Pharmaceuticals.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Condensed Consolidated Statements of Operations </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD ROWSPAN="3" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands except<BR>per share amounts)</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">OPERATING EXPENSES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">OTHER INCOME AND (EXPENSE)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change in warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">NET LOSS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">PREFERRED STOCK DIVIDENDS AND ACCRETION COSTS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">NET LOSS APPLICABLE TO COMMON STOCK</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted net loss per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Shares used in computing basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">43,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Condensed Consolidated Balance Sheet Data </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD ROWSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>At<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>At<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>in&nbsp;thousands&nbsp;(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g93463ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g93463ex99_1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)0$'`P$1``(1`0,1`?_$`*P```(!!`,!````````
M```````(!P4&"0H!`@0#`0$``04!`0``````````````!`$"`P4&!P@0```'
M`0`!!``%`P$%"0$```$"`P0%!@<($0`2$PDA,105%E$B%T%Q@9$C&-$R,R1E
MMG<9"C@1``(!`@4#`@0$`@<'!0$```$"`Q$$`"$2!08Q$P=!%%%A(C)Q@2,5
M\$*1H;'1,R0(P>%2LG0U%G)#<[,V%__:``P#`0`"$0,1`#\`W^/3#!Z88/3#
M!Z88UY?MO^]S-N'CV3`>?48?6.LDFP,I@KH3NL\PY=\T2<MWMZ6;*(GL-P(T
M<IKMJ^U5()0.51\L@G[$G'M7C?Q#?<L$>\[T6MN.$U6F4D]#2D=?M2HH9"/B
M$!.8L9P,AUQKJ?7IWOU76+SH_3K_`%:=NVIW;1U%]%=7-<9*&O\`&(0<(5"N
MSL.W_2LF<'&M@^&-28$:_M*8%!I\10$H_3>\\"XMNVPIQN6U2+;HE_2[>3PL
M?YT;,EB<WU:A)_/7'F/*]VO=HW^&ZLVHWMQJ4YJPUODP_L(S'H<;N7&G<.5]
MD5%=[5S'K6B5YHV5O6:2C@JLM`BN8$"2L8Z*FDE/U=XY`2(/4BE$IO":Z:*H
M@0?C;G/`-XX/>B.[_5VR5CVIU%%>F>EAGHD`ZJ?Q4L,\=GL7(+/?82T/T72C
MZXSU'S!]5/H?R(!PZ?K@\;[!Z88/3#!Z88/3#!Z88/3#!Z88/3#!Z88/3#!Z
M88/3#!Z88/3#!Z88/3#!Z88/3#!Z88/3#!Z88/3#!Z88/3#!Z88U?_KZ^Y;K
M3H34.%(K98CDZST_N1??H8E"PI._1VZ8"\PTE@%&Y:-"V"\7"-<T&XJ00@DN
M9!D9,BI3%.82"53["\H>!.$<6V?D<VP/O<-_QT63]Z\[+6=Z+S16*!TAB831
M:\Q5ZD4(%:CH]PVFUMTF[/=#PZ<VII;53(4`S']M!ZXN;OK[=NJ.9NH^OLOS
M-YQXWJ/+6<\\WNKYQL3312;5T?,["S!:3S?)5ZO>V3:0M[9=$X-DT81X)`71
M^4@E$R@0_&G@[AG+N&['O.[KOS7V\W5]#)/:F#VEBMJ:+/<B2$E8B*:B95K1
MJ'H,8K3;;>:UCE=9B[Z\UII737K4?+XXR/=O]Q:A@N4\S0&.95$RO7/:5YIV
M58GF^FOW[&ET2W3U=):KI/:K(1`-956NY;")K"];LOB=O'!2$3]H"<2^4^._
M'>S<EWK=[G?[UTX/L%O+<7<]NH,LT2.8XDME:JA[AJ:&>JJM2:FE8-I:Q2RN
M9F/M8JEB.I`K0+Z5-,JY8B[FWK;LO/.X6'`_><?B%LLFFXE.[I@>[\_0-QJ5
M7M3:G3#.)OF=VNGV^8L#B,L-<(Z%VBZ0=?$JT^+WD]ZP>S<<LX1P+=/';>2_
M&S[C!:6>X)9WEG>O%))&95+0SQRQ*@9'H%*LM0VJAHN=\]O:O:>[M"P"M1E:
MA/XBGIF!^)/2F-'O[B8I93[5^T(MFD4[N4VYBBT2^0B8+/)JH4L6R8JKF322
M^9P\*`F.8I">?(B!0\^OH7QI,D?CG;)Y32)+-BQ^`5Y"3E\`/QQI&^XX>##/
MKI[+YTQ6^6;9,<+3X.$L#BPRCXNC918OTL.:.A6`//TM5O,V]7\NP]GQIIG5
M_P!?;X_'U6R\D<+W:^BV[;[PR7DS!47LSK5CT%6C"C\20,>:<YVN^GNEOXDK
M:16_U-J44HS'H34Y$=`<9K?HK_\`Z%VC_P"&F?\`[WA_^SUYO_J$_P#S-A_U
MQ_\`J;$;QY_W.?\`^`?\XQ>-L^W3JZB[U>B/6G)-JQVK?9H/`,7@L46^Q?7U
MJ@GLC5VC74Z>4]WE:U8!AT+055T@,*@W5(S<?\Q'P42TL_!W"MQXS;&,[Y#O
MTW$/WIKQNRVV1N!(3;R_HK(FHQT4]TL-2Y-CWO\`;+4VZD=[NFW$FK(H"<J'
M*H_IR&'CZM^S2L<@_8#@?/6W7;'<GYPU#G/2]/LFG:.^>P<PQT&L6R.@JK7(
MF>6FF]>08R[-9<YT%F2KA4Z7DBI`#VCYSPOQ%><Y\9;GRGCUO?WO*K/=8+=+
M>`!T,,D9>1V0(7)4T`(<``Y@]<0;>P>YLWGB5FD5@,NF=/\`?ZXO3ZX^]7/=
M=F[5>Q$EFMERC#.EW&58G><U/(NF%ZSO^$5JR,['+2CN9E6,O)+OY=8GSLDV
MC8R9"@"7D!,;7^5O&J^.+3C\<Z7<.];EM`N;N&?2##/W70HJA%*J`HR8LU?7
MTQ;>V9M%BU!@[I4@_P`?&N%QP/[7KMK7V;W_`)7F:'4HGEB=L6VXSS3LC$LJ
M-CT/H3EN(H$OO%6E)!::7KSF(;(6B1-&`U9HJ'+&_P#B*B)_;UG)O"NW[)XA
MM>9V]S._,XXK2ZO[4Z>W!9;@TRV<BJ$#AB8T[FIB`7Z+E65/MB1;>+E6)N`%
M9U]`KDA3^.0K^>+P^RGN[=>8=WP/'\EOW(^1PFF8QT/JUHTGKA&X!4&;W&#Y
M^$+58E[5+U3CMY&T_P`N6(4HD>KF%$!114,7XSP?$GC?C?,.-[GON]VN^7UQ
M:;A8VT<&V&+ND77>UR,)(9:K'V@>J#/ZF`S%FWV4-S$\DJRN590`E*_57/,'
MI3$J4_O:\R?U)O/L.OV;1V;Z(SY:O6W.,XE$YP8!O:*[!V%Q6FPHR/[781K-
ML?QC-TW3.<CK]"^(4%3&\*CI;[QKMT7FY?%VVW;W>U-O,-H)UT:S'(Z"0U74
MG<B#,K&FG6A.D#+&'V:?N0LE:J&117Y&E?S&8Z=1T'3&+;3/OCV>I?6-F'1<
M%E.=.^U9;7]+R75\9D8VT?PRC*<_1L[>MPL_[0G;&UD;1D1F3.)>(E6DCBBX
MG4`,*WM`A_9-H_TV;!>^7KSBMS>W2^/DL+>YMKI6C[LWO62&TCU=LQEFN#*I
MI&*B%OMK4;./98CN#0.Y%H$5@V6>J@&=*=:^GIC/EN'4-(P_D30>NY]9$]*H
M^(O]D32%7VA+H_Q4L_7X1JH7R)W=C?N6S)L`?B=9P0`_$?7S1QWAVX<AYS:\
M'M@1N%QN(M2?^$]S0[GY1J&=O@%.-)%;M+<BV'W%Z?AGF?RZX5#ZI.W]?[+R
M#2&G36?UG).H\,TK^#Z]FM5;2[&*BXRTU>"T3,K$R8SLQ/R:#.R4NRI%]QW:
MI573-<Q/:40(7M?-/CO8N`[[:/Q"ZFON';C:=ZVGD*LS-'(\%PA9$128Y8R<
ME%%=0:G,R=RM(K65?;L6MV6H/7,9$5H.A^7KB-\>Z\[B[1V':YCDR+Y0J').
M`=)O^>']MV1+3K9JFRR6:R$"EM,U2D*)/0]7I,*U3D5V]?</TI$SU8J:JR9$
MA,!=MOO!O'7`-AV^#FS[W/S?<]I%\L=J;>.VM5G5_:I*9D:25R5!G5#'H%54
MEJ5RRVME:1(+HRM=/'JHND*M:Z:US)KU&5,4#[1?L2UGCKH#DK':-HG*>*T_
M?:ON<[<MEZPB[Q(4BH/<N:4UW78Q%2F7>F*(+6A:P+-"`J97W.!2]HE`#`:3
MX=\6;'SOC&^;]N5KO6X7VV36:16NVM"LLHN#*'8]V&4$1A`QI3Z:_E7;[&"Y
MMIKB82,8RM`A`)U5KU!Z4Q,_4?9FK\^<+81T77)7$M8O6C7_`)+J,O:ZI&6@
MV,VN$WK0Z55IZX9RQ4M(V%&&>P5F.\A#.I%U[`,D9;YR^2FY_A_`=EY/Y'W+
MBMTFX66VVEMN4BQR-'[J-[.&61(ISV]!</'IETHM<PNGJ(\-K'+=O`0ZHNK(
MTU"GH<J5^.6+[NO6VB5S[0<0XI90M05R_2N3=/W>;GW+.7-=VMLI5\B:O&1T
M8^3F$H1*`78/S'7358JKF5`!*J4H"4=;M_"=KN_#^X>0)))QO%IO5O9H@*]H
MQRPM(S,-.LN"*`AP*=5/7%BVZ-8M<DG6'I\O3^_XX5#4.B_M"@/L#J?'E.LO
M"Z=<U3.M7WFA6*R99NSR9@<MSK0*Q5T*G:SQNML64I?'\7;$3F?-$6\>"S=0
M?@`IB%]=ML_%?#MSXQGYW?P\C-W975M9S)'<685[B>&20R1ZK8E80T9&ABST
M(^JH)Q+CAVTV?N7$^I2%-&6E2.H^GIAR]2ZCOM)^PSE#DR+B*JXSS=<2Z,TF
MV33YI**6Z.F\A7S]*N-8%XA+(1+>,>EM;C]81=FX4.)$_C.GX-[N!V;AVV[A
MXNWKFTSS#=-NW"Q@C0%>TR7(FUEP5+%AVQI(=0*FH/I$CMT>SDN#76C*!\,_
MX^.%GU7KSMO9^T=HX_X&KO-D`UY7I>=3G0.P=0-=&G(MQ=]=A7MFH6?9[4LU
MF8.1<IIUYG^HDI)VO\:9C&33)[DB@YZ_9>#>/>/\`V_G7DR7=I7WJXG2RM=O
M,",(K9Q'--/+<(ZCZS2.-5J10DT8Z),5K:0VJ75]W#W"=(2@R!H220?XIUSH
MTG:G4EKXNX=OF^6:/JENVBJT6L0-=J\,C+(5&]="79>&I51KD%'N7I;$I69K
M29Q'VH"X!\6,`_E0#E$X<;X_X;9<_P#(MMQFS>:#C\US([R.5,L-E$&ED=V`
MT=Q8$.>G1W*94-,1K2W2[O%A!*PELR:5"C,U]*T_KQ8?U:=I7SM?G":LVVT^
M!S?I''-?TS!.BLWKB3]I%5#2\\GU$3-F,?+RLW+-&;ZN/F*W_.=+E,X%8$U#
M$*'C9>9?'^V^/N5QV?'IY;OB=_8V]Y8SR:2TMO.E:EE5%)#AQDJ_3IJ`3C)N
M5HEG.%A):W=`RD^H/^^OY4Q6OK:ZRT+L/'M;T#28:HP<Q0NJ^B,-B&U-9RS*
M.<U7)+PM6:[(2"<Q,33A2=>L4P.\43430.K^*:28?V^HWECA6U\$WVRVS:9)
MY(+G9K*[8RE2PDN8NXZKI5!H!^T$$@=6/7&.]MTMI%1"2"@.?SK_`'81WE'[
M$>C^I?L%VO#)/2N5,)I6!;;IV:2')5YJNA$Z\TS.J7'N6T!LE=L4M8X:HGC+
M/*NVS]-&.C7R:$6D85?P51<*>C<U\6<4X;XPV_D<-IO6Y;AN>W6]P-RAD@_;
M+>>5@7M714:75&H9"9'0M(1I^UE$ZZL(+:R291([N@;6*:`3_+EF*4(SZGIT
M.,]OKYIQI<)W]@G0=QY1XIZ7Z/SZ,KLS=<:RFQWJM1=M;2#RM/I6(33.W;S3
M6*DHB278'$X^\J+I!0?]#AZ[OQCQBQYIY`VGBNYO+'M]_>)%(T942!6K4J65
ME!_%2/EB1:Q+/<+$W0G_`&82#['?L,W_`)0^N#%>L<8HV?7/9M4FN=8,*;9X
M6TR]7=26RUX)!_'PD17K)#V%5X,LHF@P)^L5/X.!3`J80]>B>*/%W&.:^5]P
MX3R"YNK?8+*.^?NQO&L@6U?2I=GC9*::ESI'RH,3K"Q@N=P>UF8K"NK.H!^D
MTZD$8]G*OVE.>M]HXGKU`@:PPSGH_E#>=:TZ.D$9-30,UV[#[QF5$LN9F6"6
M29L&L#-VN12<)O&)G3E(C5PF9--3P?'S3PXG!]@Y!<[G),VZ[5O5G;6[*5[,
M]I=Q3S1W%-)+%TC0J5?2IUH02,K;K;O:I+K)+QR!0?0J:D'^#D<L?*Y]D=O=
M!]A])<M<!5WF"OU_CZ(H$=M6N=0I:9/-I[5=,K\E:*_1*#5<OF85XG%Q$0T)
M^YR3Q8PIK@H1-(PE*56[;^!^.^+\$VGF7DV7>);K?9)FM+;;S;H4MK=UC>::
M2X5QJ9C^G&@S6A+"II=':V4%K'<WQD+2DZ532*`=22:_D,9:_BOW^/\`X?U=
M3_RE_#OB_7_HY;^"_P`^_9/9^K_;_P!5^^_Q/^1?W_#\_P"K_1_V^_Y/[O7B
M-=L_=-6F?]F[_2J][LZ^FJFCN:,JTTZLZ4RQK/T^YZ]JOYTK_;3&.GZM/K*S
MCZY\"K%'<PV3W7>VP6UI>NB*MF4;4[I>X><N,K88:&E)MVI+6I:,@HIPS9%;
MJOU&X_HB&*0O@H!ZIYE\O;MY5Y--N*27MOQENT8;&2X:6*%DB5'94&F,,[!G
MU!`WUD$]<;#<]QDW"<N"RP940FH%!3ITSZ],+7U!]-\YO/7&]=I5#<HK+]WF
M&_,]@Y6O;*G/92;PO0L%92,595;(4TXV97BAZQ!2)F$I%`1L`H%3,8RAD@*;
MK.'^>8.-\'VWQ_?;<]YQN,WZ;C"90J7D-XP:/1]!,4ULZAXY*G.H%-51D@W5
MH;5;,K6`!@P]#J-?ZLO@>M"*U#9=U\/:#U_G//-DJNL0>,]=<N:14]MR75HV
ML/+%GK31HR-)'7"`FJ9(R9)*2SBYMU%$5&YW1G221$?>98H*IJ\3XX\B;7P7
M==TM+VRDO^#[Q:2VES;-($G,#-JB=)572L\1H0P4*26H%.DK'M+N.VD=677;
M2*5(/6F=#^(K_;TZXM;F/A[?F?4LAV]W+M.;[/OT-E:V'XW6<9SV8SW(L>SZ
M4F"S]NDXEG9K#9++/WF[R12INWSI8GZ=D46Z?O3,0$9O+_(G&9.&KX\\=;?=
MV'&9+T7=U)=3)/=74RKHC5C&D<:0Q+FJ*/J:C&A!+77%W`8/:V:,L!;42Q!8
MG\0.G]60RJ"3I1??CBNGYA]F'05VNU(G:]2MKGH&Y9;;'C8%*[>(=C0*;!S)
MX26;BHR5?0TS&K(NV1S%>-O[#J)@FJD<_P!#>'=UV^_X'96MI*CW=JC)*@/U
M1L9'9=0ZT92"K?:<P#4$#3N#JKB(>($R!F=G$"AY"].O`^/_`$*$]>E2=<>1
M\^_[M#_TX_YWQM>?1?GEW1T37]57K,JWSM]0FM+C;:Y0_3Q,K9T;/'R;N*B5
M5A(>358,FQC.3H%.D@82D.8#F`OKYP_U![G8':[+9UE0[FMR96C!JRQF,J&8
M#[:D_2#0G,@4SQ.\>VMP+J>\*,+4QZ0WH6U`D#XT'6G3&2OE3ZWLEP#<.G.C
M[A4<ET;<-PZ>U';:3K*N;1B6CYI0K_&5YFPS1C;Y8TK+I!$.6$@JHNQ49I+E
MD5"BF`";SYES3RQO?)^.[/Q2PGOK3CNW;/;VDUL)V[%Q-"SDW!B72IU!D`5P
MY70#7'LMUN$D\,<"%EA2)5(KDQ%<Z?WUQ6=9X49ZY]@.(]BVB5ID[2<GYXTO
M%7^4VBF(V-6<E[U9XRP,+2VD9%=>)9)PY&!DA3,S.L85!$JA0$0]1MD\CR;'
MXRW#@EFEQ'N%[ND%V+F.4IH6*,H8RJ@,=5:UU`?$8QQW;16K6Z5#,U:@T^']
MQ_IQ2N9N(;CRR[^P&;SN\T=K,]8;1:MDR1FTI;B)K61R,CG,14*Q$SD2RD/B
MGF4/-PZ;Q<&9695D1$A2E,/N]9N7>0['F2<9M]UMKAK?9;".UN290TERJSM)
M(R,15"RL5&K50T)J,5FNQ<&(2@E8P`<\R,JY_//^G&.2E_\`Y_DLBI7+MDRO
MKS:S=(\YZ[2=Q/.:':)RU\_3=^6F4Y;<W4!BJ3MB2HEUDCM\W571?*NO@7]K
MD[@3'$?5MP_U-MOE_O%IO.Q;=_XINMC+::((TCO4A"Z;0/=T/<-M12`4"ZA5
M0M`,;"3>S*TBO%'V74KDH#4],_B!7\":_+#N_8%]6=+^PC6\IM^EVI&)I>;X
MGN^>,F,?%NAN]>T72Y'.9K/=?H=D2D6S:#L67S5#_4I$415!V"XI&$$C*%-Y
M[XQ\R[AXOV.]L=HA+W]WN%G.2S#LO!;K.LUM,FDETN$FTD@C30,/J`I$LMQD
MLHV2,5+,I/P(%<C^-?\`;Z8K>M\9=+]`?6?/<4[3T'3+9M=LK%5S^Y=`M:3-
M1L=<:I`7RN2DI+S-1">7=I7"U4.%58OU$GHME9)P=R!"IF^$L?8^?\1XQY<B
M\@\?VNX@X_!-)-%9&5&:*1X755270`8HYG#H"NH1J$J2-1I#=V\&X"\B0B($
MD+7H2#T/P!S'RRPN-D^D^DSW6';6^$T%DVSOK#G'6\KK60&KCE6-RO6-ZH=1
MSW6M>8N/W8K)ZXM$/1F*AT4V[=85550%7V@3UU=I_J$W&VX5Q[C)M6.Z;)NM
MM<27.L:KFVLYI9[:V8::@1M,P!)(H!E4G$A=XE%O#`1G$ZFOJP4DA3\L\OP]
M:XF+H7ZX])Z,X(Y;X/MFY,8JJ4%;G.!Z<N-<A)2-GM?S?#HF+++URB^^1=EI
MLO<+'7HYZ5X]_7D:?I_Q25$?6AXMY7VGBGDO>?)-EMS/>W(OGV^)W5DM9[MF
MTR3?2.ZL4;NA1=!;5U7&*WW".WO9+T)5VUE!Z*S>I^(`)RQ[^2_K'><9=?Z/
MOF:]#:MHV:;;B]>I.O5'H*VSNKZ=.Z;0Y]53/K^PTV0<,U/VFOTEVO"EC7;5
M<Z:2GN37*0"I%Q\W\OIS[@MIQG=MKLK3=MNW!Y;:6RB2VMTMYD'>A-NH/U/*
M!+W%8`D4*DU)I=;C[RU6"2-%D1R5*@*`#U%/F<ZXC3+?K[[6Y)V;7B\:=/8=
M6N4=VWZ2Z#M&2;/BEANMUSBQW62BW^GPV86FL7>K,%8:SDCA19DDDCA&IF)[
M2G5(=5;;;SY/\?\`-]@L3SW9]QEYIMNV+91W-K=)%%/'$K"W:XCDBD8/'JJQ
MC/UFM2%(5;I;VVN8E]RC>Y1`H(-`0/B/XS-3498E3N[@[9.D>C^5NDL8T/"J
MS8>;*OM]9/4.@<?G-AHMM3V2.JT4H[<P<+=:4HDO`M8!4Z`F6,(+J$.'X$$I
MM-XV\D[#Q/BF]<2W^UW*:UW>:TD[ME=):S1>U:1J!WBER<N`<OM!'K46V5[#
M;V\MO,KE9"IJK!2--?D>M<23U;Q?>>M>'HSG"TZ94L[V:%#([E!Z;FM"<L,X
MK^MX[:*]=*[)0N9REB?O6]"4FJ\1`(M2446;M%``JQS)A[M1POG^V\(\B/RN
MRLY[K8)/<Q/;SS!IWMKJ-XG5[A44&;2]>X(P&89J`<8;>Z2WNS.JEHC7(G.A
M^)%,_P`L\1ISEQ9U`IV`CVWVYL.*W_4:5A4KSWDE/YYSNWT*C0-7LUM:6VV6
MZSN[O;+1/3MJF'$<BW1;D%)BR0,I[04.)3EV_*^?\.'!3X]\>6&X6NSW&XK>
MW,M]/%-,\D<9CCBC$,<:)&H8L6-78@=!4'+<75K[;VMFCJA?42Q!/2E!0`4^
M?7#"V[E&7LO?N-]FI7.-:0F6\WZQA3NAJ0[I65F'^CW.F6IM8F\X5^1HT9Q:
M55,B=N9L<ZIE@,!R@40'EK'FD%IXSO\`@)MW:XO-VMKP3:AI4012QE"E*DMW
M*@Z@!3IB,MP%M&MJ9LX:OX#!H_*,O>NZN9NOF]SC8Z&P/']ZS&0I"T.Z<2=D
M=;&M2%64LRFB/DFL<W@OXD<%4CMU3+_,'M,3VCY;5S2#;O'.[\&:W=Y]SOK.
MX64,`L8M1+52M*L7[F1!%*>N*I<!+5[:GWL#7\,*'KG`?6]([1UGL_@OI'*L
MTFNE*G0ZST'E/0F9V71Z!+RN9Q1("GWJH+T^VU2:C)MG!@9`[550$3'45/\`
M*)5OB2[K9/)O"-QX!9<`\E;3>W=OM,\TEE<V5Q'!,JW#%Y891+'(C(7H=0%:
M!1IJNHRH[VW>T2TO$9EC)*E2`<ZD@U^?]0IEUQ)'=/U_Z+WI7>1<YT7>%Z-G
MF0:%%:[ORV5QTK4+OINAU"GGCZ.]S*="5D0S5C$760>2A3+#(N6X"W^$_P`R
M!51U/CCR=M7C6[WS==JVT7.Z7UJUM9"Y998;>"675,+A-*]\M$J1Y:%;ZM0T
MMIQ99WR632R1H"["BZLP%)SK\3T_H/QQ2>%?K1EN#NE.FM#HV]772L1Z2A*-
M-S5.V&2EKUKC7::HH^;2>@2^I/G:1;&WLL3+.$W!%F1'8F(W`RQRHAYS^1_+
M</DGB>T;7N.V6]IR':9)426U58;8VLE"L*VX!T&-E4K1M/W44%LJWFX>]A1'
M15D3H5%!0^E/R%/A0_'+X<%\4]:\8V^]U1[NF#7?F:^;CO>Y2%49X_>(C8VT
M[L5@DK+&QK:_KZ>[J81T#(KH%6*:!.HX2(<I3D$Q3%KY*\@<(Y]8VU['MNY6
M_+K;;K.T60W4+6I2U149C"+<2:G4&GZP`)!(-*%=W5K<H"$<7`4"NH:<OE2O
M]>+.TCZ[^B.C.Y<5Z*Z"TOFY#)^7-MF=?PY'(L9L%=Z/GHY`D@WHV<:MK,[:
MY.-<TZ'3>)+2:$:R32E5FQ?^6C[_`'IS]J\I<6XKXZW#BO%[3=CO>\;>MM=^
MYND>Q1C3O3VULD:L)6H1&7<F,-U:E#>E[!!:-!`LG<=:-J8%.E"0*=>M/A\>
MM6WJ]IZSE_L'U6KO(]HSXCIW-N>J0TA+4TT/+3?1]HN,V\DB4VWG.=6X0$'G
M\80LN!0(U8/';5$A16^<WKB+RRX3!XOLKR-V;R'/NT^I5EU*EC'$@7NQ=(G>
M9OTNK.JNQ.G2,1F2V%BKU_S9D.5>B@>H]*GI^!^6+V[DYTDNN>1.A.9X>T,:
M3*;7FD]0F-LDXQQ,L(!Q,IID)(NXMJ[8.'R*'L_%,BR9A\_GZUWCOE47".;[
M9RV>%KB';[M)C&K!2X6OTAB"`3\2#C#;R]B99:5T_P!V%QZOX"LO1G)?,/-T
M3ID-4Y?G[3^6-"?VYY77\DRL:/.YXX\A'L(QM+,W,8XLIF/E!4ZZH-O/]P'_
M`#]=7POR9:<5YMO'*YK22:#=+/<(1$'"E/>UH68J0PCKF`!J]*8D0W8BN))]
M-0^K+X5(/^[^*8B#%_J0A<!^T_3OL"S;1&<5FVK46]HS6"#`O0"$UC3']1?7
MZ[5R;)+C%LXNUO:>D^=M?T)51>N%/"GQ$2(3?<@\WW')O#5GXQW:U9]VLKF$
MI>:Q]=M;K*(8I$TZBT8E**VNFA1EJ+$R)=T:?;5L9%JZD4;Y"M!^5:8\.B_7
MSV#E/7^^]9_7ST=C6:?]6,93?\\Y%T'EMGOE*&[T6%/7X32Z2_IEJKLHUG31
MRZAUFCDHMU7"RQCJ'(H1-"_:_)_!=ZX+MG"?)^U7]W^R/+[.YLKB.&7M3-K:
M"998W4IJ``93J"A0`""6HM[;2VB6MVC$QUTLI%<_0_$=/7H`!3J7QW&F=EV"
M$PE#`]KR+/K#7K7"O>@9&Z9=(VN)T2J(5Y9M.15)BTIY%U4W#ZQB5PE[G1E4
MT/!/U(>PP+>;<=O^!6MSN+<EV^^NK26%Q9+%<+&T$A>J-*VBD@5/I/TT)J=&
M8*PHFM@[&56*&M`#F.M,_P"C.AZ$4SJ&U]<3B/@],,'IA@],,+MU'RGA7960
MV#$>@J,PNU)G2"LW,I_Y2?JTXDDH2.ME,GT2_KZW:(@ZHF;ND#`(@)DE2J(*
M*I'W?'^1;OQ?<DW;99FBNTZ^JNOJCKT9#Z@_B*$`BA`.1QK_`/&G_P">IQA>
MJZ%";!J#*_<[1MV+9\\3A0<0][T*(>1S!)"`T!-!)%I51A560HOU8U9490OM
M.W%F!S%3]_WO_4![C8(UV6V,/(Y%*R,U&BA(_GBKG(6ZJ'`"?S:Z"O);IQ=-
MXWB.\NV_R,<072/N=M3&A/HM"*TS/04ZXV;:U6:]38"(JM3A(RN5J`8H1D+!
M0K)".BXN/;$`B#1DR;$30013*'Y%`/(B(CY$1'U\VW=W<WUR]Y>R/+=2,6=V
M)9F8]22<R<=5%%%!&L,*A(E%``*`#X`8KGJ/C)@],,'IA@],,?,ZR*8I@HJF
MF*IP32`YRE%10?R(F!A#WG'^@>1]5"L:T!-.N&.X&*/@0,`^1$`\"'XB'GR`
M?U$/`_\`#U2APP>0#_4/S\?[Q_(/]H^F&.A%D5!4!-5,XHJ"DJ!#E,*2H$*J
M*2@`(B10$SE-[1\#[1`?R'U4JPI4$5%1^&&!19)$AE%E4TDR>/>=0Y2$+[A`
MI?<8P@!?<8?`>?S'T"LQHH).&!15)+V?*HFG\ARI$^0Y2>]0X^")D]PA[CG'
M\``/Q'T"LWV@F@PQP"Z`J'1!9(54R@91(%""HF4W_=,<GGW%*;S^`B'X^JZ6
MIJH=)]<,=CJ)I@`G4(0#'*F`G,4H"H<0*1,/(AY.<P@`!^8B/J@!/088Y`Y!
M.9,#E%0A2F.0#`)R%.)@(8Q?/N*4XD'P(_GX'^GI0TKZ88^:;ENL(E1715,7
MQ[@35(H)?(F*'D"F$0\F(8/]H#_3U4HZYL"/RPH<<@NB*OP`LD*WQ_+\(*$%
M7XO(%^3X_/O^/W"`>?'CR/JFEM.JATUI7TPQV(HFIY$BA#@!SIC[#%-X43$2
MJ$'P(^#D,`@(?F`A^/H01U!PP"HF!BD%0@'.4QR$$Y0,<A/;[SE+Y\F*3WAY
M$/P#R']?2AI6F6&.WD!_(0'_`%_W#^7_`!]4PQU*H0X>2'(</<<GDI@,'O3,
M8BA?("/]R9RB!@_,!`0'U4@CKA@,JF4OO,H0I`(943F.4"@F4`$RGN$?'L*`
M@(C^0>?0`DT`-:X8X^9'W)%^5/W+`)D2^\ON5*4H&,*0>?*@%*("/CSX#TTM
MF:&@Z_+#''SH>U4_S)>Q`3%7/\A/:B8A0,<%3>?"8D*("(#X\`/JNEJ@4-3T
M^?X88X6<(-R>]==%`@"!1.LH1,@&$/(%]QS%#R(!^7HJLQHH)/RPQ]0$!\>!
M`?/Y>!#\?]G]?5N&/.+UF4B2AG;8J:X^$3BND!%A\^/"1A-[5!\_T\^K^W(2
M0%-1UR.6%#BVX2_42RSM@J]<NM2G[+4EBM[5782QP\K.UEP<ZB1$+!$,7B\A
M#+'42,4"N4TS"8HAX\@/J7<;9N5I;17EW;SQ6DXK&[QLJ2#XHQ`5Q_Z2<7M&
MZJ&92%/0D9'\,7;Z@XLP>F&#TPP>F&#TPP>F&#TPP>F&#TPP>F&++T?^8_X]
MO7^/`9C?OX?9`I/[B/A@%L&'>!7C//)3`9N26^(3E'P!BAX$2@/D-AM/L/W2
MV_=-7[9WX^[IZ]O4-=/GIK3%\>CN+W/LJ*_AZXUK*D#&.YXIK22-3[CF*V:=
M=M^;;!MZ;?-M.C9ATQYR):96A5!!35AF]]@MQ3L:E:CXZ<CWLM)K.4T'L<BB
MBHO]:WW<EY3</#WX-X%YMAOTM*SV[*#?=M9I3[;19/:=@7#O"Z1QA"T<K,P7
MH6J;@D5$FJ/6%S7^>E3]/TE:5)!`'H<,E=4)D]<Z$2KTI:VV9KP^T)4-]9X%
M-[,14*.@9U_]D;\D4A8V"$_<"O"2PUQHB\C""=6P@U<@DDF*W)[>UN+O:VND
MA.[B2T,PC<A6?LS_`+"NHQL4BIV^^Q20T%KK343ICI35'J`[E5K0^M#VO3(=
M*]?Y:XLRN-[V76L')&3&B+3;2B_7^%Q<KUM9M49_F\.D+FGD!]!8GM;J'J.X
MGD58I9@6,<3;HJ*$TB^,9DN9=M/NWVT[)N1FCM!;M<[UV@)`94O_`&$7NNP>
MV'EM-(D#]Q85J;=HP)%TO>Q3M/4+IU2TSS#Z!JIEFO7K3TIF,[SRE2L*YYG!
M*NSQQA9F;*LL]"=9S)6B7UVQ6U+G?JX'5BZ?8RD5",*9J3Y\"QI"%=N)Z9:R
MHO"KRCAL#8PZ_>A>+NMV;QK]K1FD,`G6-;9(O?;;1-O*L[2VX%-$JK#$T7;*
MPJ^L8LEU=QM6O34TK32!KCR3K4=*'(4IEB$LT']%GM8=SJ9+)D18;)E,>@.F
ME8JE0JV=K<S;$WSIG?+=H2-_IS:8CK&#MW0'-VA%0>QPQC260:OP*]'HMW_4
MW29+;]+?.Y<^Z?;]4KB<;A:F<PQ0&&4JT>E;U;24:).\\#/'^GC-+G(0,I:M
MJ*9YZUK0"AI2FK2<C4BHRPU^X+1[7FOA0VFQV*SICXW;T7"6NS+>J9RWG%N?
M/$9(P:\5!7,'EGC2^1A&4:F@X>F]P-730WM$.*XZLC\MY(-H?<(Q[^(@VR&2
M<H+WZE<,\5(V_P#>=R0G\Z.*XBP5-Q/V]8&L?;F::_6I&7QKT]0<*W9T&1=7
MUD`E+&O?QSG7VMD-.P.3-;,FL/,>1GAYN?)3[&\Z(5FPFFQ4WD7<#$J(@\=*
M1\@$JSBDG_96C2'9+*J1#;/=VICT/<F.G[A<ZT3NQBQT:"2LEK6Z^E!+%V9)
MVCE)_A)D-&I:9M3[V^(T?FOU=*BA-).Z:>6']=JCZ^US)?Y6ZM71B,;5[[=*
MW_BZ#O:F9<DEKTCG=[V.@_Q"U::SK;9P=JRDZY#.7,6\FR1CI!PS][[3\1CM
M>U91[;+?>R$%B6DABD]P\/N-RUK/#:S=V.W,A4,\<\JK(MN9D9)*1XH`-*A"
M^C2F8!U$5?J%-0*_`D5`J*'*;.2CS@]U7UI)(54MF99RZ-J$^+N(/:[-9%:?
MA@&11J$BR)I=&8Q[H2&55_>[#1WA`2+#IMEQ7,'/<W%M_P#SBV>(S>S:Z'MT
MHW;CC$MYF95/MYBPK0=J"[7ZC.772,8;JGLU(KIK](]`*MZC(_T!OCB-ZH&9
M!HFP#@IW(V7_`.S-\+TO+B6+%T<*Q_T-2@($;FMJQZ<-2"V?O9E3OP!`7W[B
M5N4'WR&];:]_>/VJP_\`)0/9_P#B"T_<3=]CN?NZUKVAW>[V^S0)GH[18]N@
MQD?N=M._]OMOY]5*]SY9UI3I\O3"R4=)(;GF@Q\A?$](-1:@@F2(B,;6T))L
MO]<4(BPDX]6M3B'3;BW14L9RY9L1(EF4A+D,V=.V;LZ+HG7[BS>PN^XML=I]
MS*?J:Z$!(WUR582(=O$3+I5GJ;](B'1)$#(9+_8U=/:J?^*G^+\QHI\_O`Z`
MC+#0XH]+_EO-W_/E:P?VM)#*6Y*KCMWGO^G2P68G/'5:=AEKC?X_/OWFG;6X
MK+ANM(1X5J=719,XE&0>JK/"+L>.Y#&?V.[CY1-N7U+<GN74*>^2/WVW:%BA
M:?1+:"0,$?OP@NT[11A8RLD:8?HL)R_\V;`:P-:4H*YK7UJ,ZT&6<*-1FR3>
M.LJX2@N;VM$<T.7%ENJE08[5&Y"WY0I);#"T2D6I*1M<UF<J+>;,E)U2P,%X
M^;=S195@]*T(=]T#^W-O?R7?N1MHDOP(XNZ;1KD[E+H>::/3&EPM8:QW$#AX
MEMS#+'K(CRG31BVK15\A73JUFE2,@>F1!J--"*Y.'S^G=%.>NE$Y)UT,TFC\
M:9,G!.]!84"0OS439)J0,W6=1^2248@_;I.A]S!NNZ;3:CTHE.L03)&+PO)S
MMXY3M!A7:VMQO]SK$#3+"?\`,V]1.URK$&GWL%:()F%-&!BSZ._'3MZ>\W2M
M/N'75_7Z8CSF>1LO^4(9[DE/Y^&JCN#9O4*SE>CPP902+#F*W!9I@EYSS*QD
M5)-0IV8MXV?KI9\GQD"0?&%1(R6SY=%:?LTD>^3[I[W]N)EDN8&]SJ_<(NVO
M9GN=.G[M4D,_9-3VHQ0UNN`O;(E,FK1F6&?WBF1;\:D&GP&//;SY@C);XX:M
MW,C6&_5.<+52(V9[-PV`2V'EM4*748Q"Q),)Y.O8<MU4-F/,/C1<FQ3ERQ!'
MC0]?-&J%OL1N[0[8KE4O#LLXD:U"/>K=]M_;L4)37=C;O;B).Y&YB[Y1Q="4
M&Y>[2/\`X^T:Z?NU4.G+U;1IIF#2M#JKBV+*K0_Y%5TD6&'A-R<9RJIBSZCR
MTR-II40EO-A709\.1;^%"9T^LOU3G:S+DSRH,VA4CNG2#F!4:,TIEHNY>TF+
M-N/MT?<?=B94[<K&S0$[NROHMY!DT2Z;IFJ$1DN0\C7+KH?OTU?57H?I'^)\
M#\/N^`HU3B+LJ>5D&ED>&KV+J9%']&YZWL->T2Y%2RZVO"P?3B1Y?>+B2B+7
MG.Z@O.KQSB$CM*@K19DK6V8MY%ZHU<LG+3<[U'>:XD[NX#?&VJ<H\$5;B(:]
MO.FSB[PAGE"!UF>PFM[<VS2-%&'21'R2ANA+]SMFA`S'V?:*T)I6I4@::T'4
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2Z@M=2TS-/EZ=/A\%R%1GC__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
